Ensysce Biosciences, Inc. Common Stock (ENSC) Stock Price

ENSCStock

$0.52−79.83%52W

Market Cap$10.08M

P/E—

PEG Ratio—

Div yield—

Beta1.08

ENSC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-10.23%

Price vs S&P 500 (4W)24.41%

VGM Score48.48

Book Value / Share (Quarterly)$0.70

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)26.21%

Cash Flow / Share (Quarterly)$-0.55

Price vs S&P 500 (YTD)-55.59%

Net Profit Margin (TTM)-280.48%

EPS (TTM)$-2.75

10-Day Avg Trading Volume0.91M

EPS Excl Extra (TTM)$-2.75

EPS (Annual)$-3.98

ROI (Annual)-199.18%

Net Profit Margin (5Y Avg)-522.58%

Cash / Share (Quarterly)$0.04

Revenue Growth QoQ (YoY)-15.10%

ROA (Last FY)-142.62%

Revenue Growth TTM (YoY)-39.29%

EBITD / Share (TTM)$-1.91

ROE (5Y Avg)-10.24%

Operating Margin (TTM)-281.32%

Cash Flow / Share (Annual)$-5.52

P/B Ratio3.14x

P/B Ratio (Quarterly)1.04x

Net Income / Employee (Annual)$-1,272,000

EV / Revenue (TTM)2.13x

Net Interest Coverage (TTM)-541.15x

ROA (TTM)-320.46%

EV / EBITDA (TTM)6.43x

EPS Incl Extra (Annual)$-3.98

Current Ratio (Annual)2.42x

Quick Ratio (Quarterly)0.37x

3-Month Avg Trading Volume10.37M

52-Week Price Return-79.83%

Revenue / Employee (TTM)$562,600

Tangible BV / Share (Quarterly)$0.52

P/S Ratio (Annual)1.99x

Asset Turnover (Annual)0.93x

52-Week High$2.75

Operating Margin (5Y Avg)-498.67%

EPS Excl Extra (Annual)$-3.98

26-Week Price Return-0.33%

Quick Ratio (Annual)1.65x

13-Week Price Return83.27%

Total Debt / Equity (Annual)0.08x

Current Ratio (Quarterly)0.70x

Enterprise Value$9.60M

Asset Turnover (TTM)1.14x

Revenue / Employee (Annual)$633,300

Pretax Margin (Annual)-200.85%

Cash / Share (Annual)$2.57

3-Month Return Std Dev147.92%

Net Income / Employee (TTM)$-1,578,000

ROE (Last FY)-215.28%

Net Interest Coverage (Annual)-788.52x

EPS Basic Excl Extra (Annual)$-3.98

Receivables Turnover (TTM)5.55x

Total Debt / Equity (Quarterly)0.10x

EPS Incl Extra (TTM)$-2.75

Receivables Turnover (Annual)7.02x

ROI (TTM)-332.77%

P/S Ratio (TTM)2.24x

Pretax Margin (5Y Avg)-523.41%

Revenue / Share (Annual)$1.98

Tangible BV / Share (Annual)$-6.95

Price vs S&P 500 (52W)-95.36%

Year-to-Date Return-43.66%

5-Day Price Return-6.76%

EPS Normalized (Annual)$-3.98

ROA (5Y Avg)-217.56%

Net Profit Margin (Annual)-200.84%

Month-to-Date Return24.65%

Cash Flow / Share (TTM)$-7.50

EBITD / Share (Annual)$-4.00

Operating Margin (Annual)-202.12%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-9.12%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.75

P/TBV (Quarterly)1.86x

P/B Ratio (Annual)2.18x

Pretax Margin (TTM)-280.49%

Book Value / Share (Annual)$2.73

Price vs S&P 500 (13W)80.59%

Beta1.08x

Revenue / Share (TTM)$0.35

ROE (TTM)-374.96%

52-Week Low$0.23

vGradeB

gGradeD

mGradeC

vgmGradeC

ENSC Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.50	-$0.20	+60.46%(+$0.30)
Q1 2026	May 15, 2026	-$0.73	-$0.52	+28.77%(+$0.21)
Q4 2025	Mar 30, 2026	-$1.26	-$0.75	+40.48%(+$0.51)
Q3 2025	Nov 14, 2025	-$0.93	-$1.29	-38.71%(-$0.36)
Q2 2025	Aug 13, 2025	-$1.28	-$0.79	+38.28%(+$0.49)

ENSC Analyst Recommendations

Apr 2024

May 2024

Jun 2024

Jul 2024

4.14

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ENSCEnsysce Biosciences, Inc. Common Stock	B	D	C	2.2x	-39.3%	—	—	$0.52
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Ensysce Biosciences, Inc. Common Stock

Ensysce Biosciences is a clinical-stage biotech company developing safer opioid medications using proprietary abuse-resistant and overdose-protection technologies. The company's pipeline includes two drug platforms—the TAAP platform for abuse resistance and the MPAR platform for overdose protection—targeting the severe pain management market while reducing addiction and overdose risk. By addressing a critical unmet need, Ensysce aims to provide healthcare providers with effective pain treatment options that limit potential for drug abuse.

ENSC Insider Transactions

BuyAug 7, 2026
GOWER ROBERT G
Director
Shares: 908,614Value: $444,169

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

PLURPluri Inc. Common StockBiological Products
PASGPassage Bio, Inc. Common StockBiological Products
INABIN8bio, Inc. Common StockBiological Products
INTSIntensity Therapeutics, Inc. Common stockBiological Products
BNKKBonk, Inc. Common StockCosmetics & Toiletries
BONBon Natural Life Limited Class A Ordinary SharesPharmaceutical Preparations
TANHTantech Holdings Ltd. Class A Common SharesIndustrial Chemicals
BMRABIOMERICA INCIn Vitro Diagnostics

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$0.23

High$2.75